Clinical trials: Clinical Trial, Phase I
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.
- Trial name
- NCT06770569
- Testing
- HRS-3802
- Where
- 6 sites in Australia, China
- Volunteers
- 100 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Breast Cancer
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06115902
- Testing
- TQB2102 for injection
- Where
- 20 sites in China
- Volunteers
- 153 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Solid Tumor, Adult
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in…
- Trial name
- NCT06026254
- Testing
- IMSA101, Immune Checkpoint Inhibitor
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
Enterotoxigenic E. Coli (ETEC) Infection
ACE527 Safety and Immunogenicity Study
The purpose of this study is to evaluate the safety and immune response to ACE527.
- Trial name
- NCT00901654
- Testing
- ACE527 vaccine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Participants With Advanced Solid Tumor Malignancies
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts.
- Trial name
- NCT07686068
- Testing
- VBC106
- Where
- 4 sites in United States, Australia
- Volunteers
- 260 people
- Sponsor
- VelaVigo Bio Inc
Hepatic Impairment
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child-Pugh classification) on the pharmacokinetics (PK) of ABL001 after a single oral dose.
- Trial name
- NCT02857868
- Testing
- ABL001
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Insomnia Chronic
STATE Trial: SusTained Attention Training to Enhance Sleep - Remote
This study is a validation study to document the acceptability of the Tonic and Phasic Alertness Training (TAPAT) program in older adults with chronic late-life insomnia.
- Trial name
- STATE (NCT03604380)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Active Comparator
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Posit Science Corporation
COVID-19, Coronavirus Pneumonia
A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
This study is divided into two parts, including Part I: a randomized, open-label, positive drug-controlled, single ascending dose (SAD) study, a food effect (FE) study, and Part II: a randomized, double-blind, placebo-controlled…
- Trial name
- NCT06860282
- Testing
- Remdesivir, CX2101A
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Heronova Pharmaceuticals
HER2-expressing Cancers
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable)…
- Trial name
- NCT02892123
- Testing
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 279 people
- Sponsor
- Jazz Pharmaceuticals
Hepatocellular Carcinoma (HCC)
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular…
- Trial name
- NCT06841185
- Testing
- HLX13, US-sourced YERVOY®, EU-sourced YERVOY®
- Volunteers
- 656 people
- Sponsor
- Shanghai Henlius Biotech
Dry Eye Disease, Ocular Surface Disease
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
This is a phase I study evaluating safety and tolerability of PRO-229 ophthalmic solution through he incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), incidence of chemosis, and changes in…
- Trial name
- NCT06370585
- Testing
- PRO-229, Lagricel® Ofteno PF
- Where
- Mexico
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Esophageal and/or Cardia Cancer, Melanoma
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal…
- Conditions
- Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
- Trial name
- NCT07518043
- Testing
- HLX18, OPDIVO®
- Where
- 7 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Solid Tumors
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
CLBQ707A1101 assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients.
- Trial name
- NCT00441610
- Testing
- Gimatecan
- Where
- Japan
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy
- Trial name
- NCT01406574
- Testing
- OPB-31121, OPB-31121 phase2
- Where
- 2 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects
Study to investigate the effect of food on the relative bioavailability of a 2.5 mg linagliptin+1000 mg metformin fixed dose combination (FDC) tablet
- Trial name
- NCT02223026
- Testing
- Linagliptin/metformin FDC, high-fat, high caloric meal
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Retinitis Pigmentosa
Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa
The purpose of this study is to evaluate the safety of intravitreal injection of autologous bone marrow stem cells in patients with retinitis pigmentosa by a prospective, single-center, randomized, parallel, double-blind, phase I…
- Trial name
- TC/RP (NCT02280135)
- Testing
- Intravitreal injection of Autologous bone marrow Stem Cell, Subconjunctival injection of saline
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Red de Terapia Celular
Non-small Cell Lung Cancer (NSCLC)
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as…
- Trial name
- STX-241 FIH (NCT06567015)
- Testing
- STX-241
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 171 people
- Sponsor
- Pierre Fabre Medicament
Myelodysplastic Syndrome
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002…
- Trial name
- NCT02002936
- Testing
- SyB C-1101
- Where
- 4 sites in Japan
- Volunteers
- 1 people
- Sponsor
- SymBio Pharmaceuticals
Hemophilia A, Hemophilia B
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
The purpose of this study is to evaluate the safety, tolerability, immunogenicity , PK, and PD of a single dose of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors （Part A）and to evaluate the…
- Conditions
- Hemophilia A, Hemophilia B, Factor VII Deficiency
- Trial name
- NCT07644832
- Testing
- SR604
- Where
- 9 sites in China
- Volunteers
- 76 people
- Sponsor
- Shanghai RAAS Blood Products Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.